Inhibins as Novel and Targetable Regulators of Angiogenesis


Reference #: 01214

The University of South Carolina is offering licensing opportunities for the use of a novel and targetable regulator of angiogenesis.



This researcher has identified Inhibin as a heterodimeric molecule that could be considered a novel and robust regulator of angiogenesis. Inhibin has been identified as a biomarker for ovarian cancer. It has been shown to act as a tumor suppressor in gonadal tumors in mice experiments, and has also been identified in elevated levels in ovarian, prostate, and pancreatic cancers.


Invention Description:

The subject invention is a method or mechanism of action that would make it possible for several diseases inflicted by vascular abnormalities to be controlled and/or treated therapeutically.


Potential Applications:

The invention is predicted to be used (alone) to block cancer angiogenesis or in combination with anti-VEGF therapies in all cases that anti-VEGF therapies are used. It can also be explored in diseases such as Polycystic Ovary Syndrome, HHT, preeclampsia, and macular degeneration.


Advantages and Benefits:

1) Inhibin levels are very low in post-menopausal women (and in men) and hence when elevated, targeting it should have limited adverse effects as it has no normal function at this stage

2) Anti-VEGF therapies are typically quite toxic due to wide spread effects and the requirements for VEGF. Being able to lower the dose of these therapies by combining them with anti-Inhibin therapies would minimize side effects for patients.


Patent Information:
For Information, Contact:
Technology Commercialization
University of South Carolina
Mythreye Karthikeyan
Priyanka Singh
© 2019. All Rights Reserved. Powered by Inteum